Read More I am in Australia but i am from Nepal. We don't have seroquel xr in Nepal. Though i found seroquel from india it will be very expensive. India is a neighbor country. I will be insolvent in few years cause Nepalese earning cannot afford seroquel.
But without medicine I will be fully disable and sex zero. SO i will be gay in Nepal. But i won't be gay abroad. I don't care about sex zero if i don't have disability. I can adopt kid. But Disability is so hard and painful i really scare. In some cases, a prior increase in body weight has been reported which may be a predisposing factor.
Appropriate clinical monitoring is advisable in accordance with utilised antipsychotic guidelines. Patients treated with any antipsychotic agent including quetiapine, should be observed for signs and symptoms of hyperglycaemia such as polydipsia, polyuria, polyphagia and weakness and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control.
Weight should be monitored regularly. Lipids Increases in triglycerides, LDL and total cholesterol, and decreases in HDL cholesterol have been observed in clinical trials with quetiapine see section 4.
Lipid changes should be managed as clinically appropriate. QT prolongation In clinical trials and use in accordance with the SPC, quetiapine was not associated with a persistent increase in absolute QT intervals. In post-marketing, QT prolongation was reported with quetiapine at the therapeutic doses see section 4.
As with other antipsychotics, caution should be exercised when quetiapine is prescribed in patients with cardiovascular disease or family history of QT prolongation. Also, caution should be exercised when quetiapine is prescribed either with medicines known to increase QT interval or with concomitant neuroleptics, especially in the elderly, in patients with congenital long QT syndrome, congestive heart failure, heart hypertrophy, hypokalaemia or hypomagnesaemia see section 4.
Cardiomyopathy and myocarditis Cardiomyopathy and myocarditis have been reported in clinical trials and during the post-marketing experience, however, a causal relationship to quetiapine has not been established.
Treatment with quetiapine should be reassessed in patients with suspected cardiomyopathy or myocarditis. Withdrawal Acute withdrawal symptoms such as insomnia, nausea, headache, diarrhoea, vomiting, dizziness and irritability have been described after abrupt cessation of quetiapine. Gradual withdrawal over a period of at least one to two weeks is advisable see section 4.
Elderly patients with dementia-related psychosis Quetiapine is not approved for the treatment of dementia-related psychosis. An approximately 3-fold increased risk of cerebrovascular adverse events has been seen in randomised placebo controlled trials in the dementia population with some atypical antipsychotics. The mechanism for this increased risk is not known.
An increased risk cannot be excluded for other antipsychotics or other patient populations. Quetiapine should be used with caution in patients with risk factors for stroke. In a meta-analysis of atypical antipsychotics, it has been reported that elderly patients with dementia-related psychosis are at an increased risk of death compared to placebo. The patients in these trials died from a variety of causes that were consistent with expectations for this population.
Dysphagia Dysphagia see section 4. Quetiapine should be used with caution in patients at risk for aspiration pneumonia. Constipation and intestinal obstruction Constipation represents a risk factor for intestinal obstruction. Constipation and intestinal obstruction have been reported with quetiapine see section 4. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with quetiapine and preventive measures undertaken.
Pancreatitis Pancreatitis has been reported in clinical trials and during post marketing experience. Among post marketing reports, while not all cases were confounded by risk factors, many patients had factors which are known to be associated with pancreatitis such as increased triglycerides see section 4.
Additional information Quetiapine data in combination with divalproex or lithium in acute moderate to severe manic episodes is limited; however, combination therapy was well tolerated see section 4. The data showed an additive effect at week 3. Lactose Seroquel tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
Misuse and abuse Cases of misuse and abuse have been reported. Caution may be needed when prescribing quetiapine to patients with a history of alcohol or drug abuse. Caution should be exercised treating patients receiving other medications having anti-cholinergic muscarinic effects see section 4. Cytochrome P CYP 3A4 is the enzyme that is primarily responsible for the cytochrome P mediated metabolism of quetiapine. In an interaction study in healthy volunteers, concomitant administration of quetiapine dosage of 25 mg with ketoconazole, a CYP3A4 inhibitor, caused a 5- to 8-fold increase in the AUC of quetiapine.
On the basis of this, concomitant use of quetiapine with CYP3A4 inhibitors is contraindicated. It is also not recommended to consume grapefruit juice while on quetiapine therapy. In a multiple dose trial in patients to assess the pharmacokinetics of quetiapine given before and during treatment with carbamazepine a known hepatic enzyme inducer , co-administration of carbamazepine significantly increased the clearance of quetiapine.
As a consequence of this interaction, lower plasma concentrations can occur, which could affect the efficacy of quetiapine therapy.
Co-administration of quetiapine and phenytoin another microsomal enzyme inducer caused a greatly increased clearance of quetiapine by approx. The pharmacokinetics of quetiapine were not significantly altered by co-administration of the antipsychotics risperidone or haloperidol.
Concomitant use of quetiapine and thioridazine caused an increased clearance of quetiapine with approx. The pharmacokinetics of quetiapine were not altered following co-administration with cimetidine. The pharmacokinetics of lithium were not altered when co-administered with quetiapine. In a 6-week, randomised, study of lithium and Seroquel XL versus placebo and Seroquel XL in adult patients with acute mania, a higher incidence of extrapyramidal related events in particular tremor , somnolence, and weight gain were observed in the lithium add-on group compared to the placebo add-on group see section 5.
The pharmacokinetics of sodium valproate and quetiapine were not altered to a clinically relevant extent when co-administered. Never take quetiapine in larger amounts, or for longer than recommended by your doctor. High doses or long-term use of quetiapine can cause a serious movement disorder that may not be reversible.
Symptoms of this disorder include tremors or other uncontrollable muscle movements. Take this medicine with a full glass of water. You may take quetiapine with or without food. Do not crush, chew, or break an extended-release tablet. Quetiapine may cause you to have high blood sugar hyperglycemia. If you are diabetic, check your blood sugar levels on a regular basis while you are taking quetiapine.
You should not stop using quetiapine suddenly. Stopping suddenly may make your condition worse. Blood pressure may need to be checked often in a child or teenager taking quetiapine. Quetiapine can cause you to have a false positive drug screening test.
If you provide a urine sample for drug screening, tell the laboratory staff that you are taking quetiapine. Store at room temperature away from moisture and heat. What happens if I miss a dose?
© Copyright 2017 Seroquel xr 200 price - Saving Is Easy. Prepay Online & Pick Up At A Local Pharmacy. We Price Match..